Defining the safety profile of pandemic influenza vaccines

[1]  Z. Vajo,et al.  Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial , 2010, The Lancet.

[2]  Xiaofeng Liang,et al.  Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial , 2010, The Lancet.

[3]  M. Blatter,et al.  Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials , 2010, The Lancet.

[4]  S. Black,et al.  Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines , 2009, The Lancet.

[5]  X. Zhang,et al.  A novel influenza A (H1N1) vaccine in various age groups. , 2009, The New England journal of medicine.

[6]  K. Hoschler,et al.  Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.

[7]  C. Wichems,et al.  Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.

[8]  J. Stockman.  Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials , 2011 .

[9]  Changgui Li,et al.  A Novel Influenza A ( H 1 N 1 ) Vaccine in Various Age Groups , 2009 .

[10]  C. Wichems,et al.  Response after One Dose of a Monovalent Influenza A (H1N1) 2009 Vaccine — Preliminary Report , 2009 .

[11]  A. Act,et al.  Trial of Influenza A (H1N1) 2009 Monovalent MF59-Adjuvanted Vaccine — Preliminary Report , 2009 .